Teacher Retirement System of Texas Makes New $1.23 Million Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Teacher Retirement System of Texas acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund acquired 8,180 shares of the medical research company's stock, valued at approximately $1,231,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Two Sigma Securities LLC raised its stake in shares of Charles River Laboratories International by 4.3% during the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after purchasing an additional 81 shares during the period. Wahed Invest LLC increased its stake in Charles River Laboratories International by 6.5% in the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock worth $244,000 after acquiring an additional 81 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Charles River Laboratories International by 16.3% in the 4th quarter. Jones Financial Companies Lllp now owns 641 shares of the medical research company's stock worth $118,000 after acquiring an additional 90 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its stake in Charles River Laboratories International by 0.7% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 15,694 shares of the medical research company's stock worth $2,897,000 after acquiring an additional 102 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Charles River Laboratories International by 2.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock worth $763,000 after acquiring an additional 105 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Trading Up 0.4%

CRL stock traded up $0.55 during trading on Wednesday, hitting $154.97. 526,556 shares of the company traded hands, compared to its average volume of 1,030,790. The firm has a market capitalization of $7.61 billion, a PE ratio of -238.42, a P/E/G ratio of 5.35 and a beta of 1.49. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a 50-day moving average of $146.43 and a 200-day moving average of $151.17. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. Charles River Laboratories International's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.27 EPS. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on CRL shares. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research note on Wednesday, May 14th. Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. Mizuho decreased their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Finally, Robert W. Baird upped their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average target price of $174.54.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).